Segment Reporting - Significant Segment Expenses (Details) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Segment Reporting [Abstract]
Sales		$ 729,394	$ 554,908	$ 1,479,926	$ 1,047,532
Cost of sales (excluding depreciation expense)		293,838	190,839	569,275	352,496
Research and development expense		269,036	716,979	1,317,416	1,797,759
Other research and development expense	[1]	1,112,986	1,586,262	4,447,507	4,252,088
Total research and development expense		1,382,022	2,303,241	5,764,923	6,049,847
Sales and marketing expense		1,143,805	1,572,189	3,037,349	2,847,866
General and administrative expense		1,477,800	1,530,791	4,817,485	4,645,412
Depreciation and amortization expense		85,697	76,288	256,835	215,144
Total operating expenses		4,089,324	5,482,509	13,876,592	13,758,269
Total other expense, net		(541,053)	(289,262)	(1,715,829)	(630,303)
Loss before income taxes		(4,194,821)	(5,407,702)	(14,681,770)	(13,693,536)
Income tax benefit		0	1,158	(4,188)	(592)
Net loss		$ (4,194,821)	$ (5,408,860)	$ (14,677,582)	$ (13,692,944)

[1] Other research and development expense include clinical affairs, regulatory, manufacturing and quality assurance expenses.